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Edited by Veli-Pekka LehtoAbstract Dietary anthocyanins are widely distributed in fruits,
vegetables and red wines, and there are several reports
mentioning their beneﬁcial eﬀects. Previously we reported that
cyanidin-3-glucoside (Cy3G) induced endothelial nitric oxide
synthase (eNOS) expression and nitric oxide (NO) production in
bovine vascular endothelial cells. In the present study, we show
that Cy3G regulates phosphorylation of eNOS and Akt, aﬀects
the interaction between eNOS and soluble guanylyl cyclase, and
increases cyclic guanosine monophosphate (cGMP) production.
Our results suggest that Cy3G enhances vascular eNOS activity,
and may help to improve vascular endothelial function.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Cardiovascular diseases such as atherosclerosis and hy-
pertension are major factors aﬀecting health. The regular
drinking of red wine containing phenolic compounds has
been reported to reduce the incidence of coronary heart
disease in France, a phenomenon known as the ‘‘French
paradox’’ [1]. Dietary polyphenols are widely distributed in
vegetables, fruits, and beverages such as tea and wine.
Several recent studies have demonstrated that polyphenols
such as epigallocatechin-3-gallate [2], resveratrol [3], quer-
cetin [4], and delphinidin [5] enhance nitric oxide (NO)
output to improve endothelium-dependent vascular relaxa-
tion. Anthocyanins are polyphenols and there are several
reports mentioning their beneﬁcial eﬀects. For example, cy-
anidin-3-glucoside (Cy3G) exhibits free radical scavenging
activity [6], suppresses inﬂammation [7], protects against
endothelial dysfunction [8] and decreases myocardium da-
mage [9].* Corresponding author. Fax: +81-798-45-9951.
E-mail address: jwxu@mwu.mukogawa-u.ac.jp (J.-W. Xu).
Abbreviations: BAECs, bovine vascular endothelial cells; cGMP, cyclic
guanosine monophosphate; Cy3G, cyanidin-3-glucoside; eNOS, en-
dothelial nitric oxide synthase; NO, nitric oxide; sGC, soluble guanylyl
cyclase; VASP, vasodilator-stimulated phosphoprotein
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(eNOS) plays a major role in maintaining cardiovascular
homeostasis by governing blood pressure, improving en-
dothelial function, suppressing vascular smooth muscle mito-
genesis, and inhibiting leukocyte adhesion and platelet
aggregation. Several studies have reported that estrogen, high-
density lipoprotein, shear stress, vascular endothelial growth
factor, and bradykinin induce the phosphorylation of eNOS at
Ser1179 via Akt and ERK1/2 MAP kinases in endothelium-
dependent vasomotion [10–16]. On the other hand, agonist
stimulation also results in the dephosphorylation of eNOS at
Ser116 by calcineurin [17].
In a previous study, we reported that Cy3G induced eNOS
expression and NO production [18]. In the present study, we
examined whether Cy3G quickly stimulates eNOS activity.
The results showed that Cy3G brought about phosphorylation
at Ser1179 and dephosphorylation at Ser116 in eNOS, caused
formation of the soluble guanylyl cyclase (sGC)/eNOS com-
plex, and increased cyclic guanosine monophosphate (cGMP)
production in BAECs.2. Materials and methods
2.1. Materials
Cyanidin-3-glucoside (Cy3G) was purchased from Extrasynthese
(Lyon, France), PD98059 from Sigma (St. Louis, MO), wortmannin
from BIOMOL Research Laboratories (Plymouth Meeting, PA),
and cyclosporin A from Wako Pure Chemical Industries (Osaka,
Japan). Anti-eNOS mouse monoclonal antibody was obtained from
Calbiochem (San Diego, CA). Anti-ERK1/2 MAP kinase rabbit
antibody and the direct cGMP enzyme immunoassay kit were pur-
chased from Sigma. Anti-Src kinase rabbit polyclonal antibody,
anti-phospho-Src (Tyr416) mouse monoclonal antibody, anti-phos-
pho-ERK1/2 MAP kinase (clone 12D4) mouse monoclonal anti-
body, anti-phospho-serine/threonine mouse monoclonal IgGs
mixture, anti-phospho-eNOS (Ser116) rabbit IgG, Akt cDNA (dom.
neg.) in the pUSEamp vector and the wild-type Akt cDNA vector
were purchased from Upstate Biotechnology (Lake Placid, NY).
Anti-Akt1 mouse monoclonal IgG, anti-phospho-Akt (Ser473) rab-
bit polyclonal IgG, anti-vasodilator-stimulated phosphoprotein
(VASP) goat IgG, anti-sGC-b1 rabbit IgG, and protein A/G Plus
agarose were from Santa Cruz Biotechnology (Santa Cruz, CA).
Anti-phospho-eNOS (Ser1177) rabbit IgG was obtained from Cell
Signaling Technology (Beverly, MA). Anti-activated-VASP (Ser239)
mouse IgG was from nanoTools Antikorpertrchnik (Taningen,
Germany). Fugene 6 transfection reagent was purchased from
Roche Diagnostics (Mannheim, Germany). Opti-MEM I and G418
were purchased from Invitrogen Corp. (Carlsbad, CA). The ECL
plus Western Blot Detection System was from Amersham Bios-
ciences Corp. (Piscataway, NJ).blished by Elsevier B.V. All rights reserved.
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Bovine artery endothelial cells (BAECs) were obtained from the
Human Science Research Resources Bank (Osaka, Japan). Cell culture
was performed as described previously [18].
2.3. Immunoprecipitation and western blotting
Preparation, immunoprecipitation, and immunoblot analysis of
protein extracts were performed as described previously [18,19].
2.4. Transfection
Transfection of the dominant negative Akt cDNA and wild Akt
cDNA vector were performed as described previously [18].
2.5. Detection of cyclic GMP activation
Intracellular cyclic GMP activation was measured with ELISA im-
munoassay kits according to the manufacturer’s instructions. In brief,
cell lysates and primary antibody were dispensed into designated wells
of a 96-well immunoplate and incubated for 2 h at room temperature.
After ﬁve washes, cGMP-alkaline phosphatase was added to each well
and incubated for 1 h. Finally, the microplate was washed and a p-
nitrophenyl phosphate substrate solution was added to each well. After
30 min, the reaction was terminated with HCl. The absorbance at 405
nm was measured within 20 min.
2.6. Data presentation
Statistical analysis was performed with an ANOVA test when ap-
propriate. The data are expressed as meansS.E.M. Values of
P < 0:05 were considered signiﬁcant.Fig. 1. Cy3G-induced phosphorylation at Ser1179 and depho-
sphorylation at Ser116 of eNOS in BAECs assayed by Western blot-
ting. (A) BAECs were treated with the indicated concentration for 12
min. (B) BAECs were treated with 0.5 lmol/L of Cy3G for the period
indicated. Top: an original bolt. Bottom: results of densitometric
analyses. Data are means S.E.M. (n ¼ 3, *P < 0:01).3. Results
3.1. Cy3G regulated both phosphorylation at Ser1179 and
dephosphorylation at Ser116 of eNOS
Following treatment with Cy3G at 0.005–5 lmol/L for 12
min, the eNOS in BAECs showed phosphorylation at Ser1179
and dephosphorylation at Ser116 (Fig. 1A), with a maximal
increase (about 2-fold of the control, n ¼ 3) of 0.5 lmol/L at
12 min. The eﬀective concentration for the dephosphorylation
at Ser116 was 0.5–5 lmol/L (Fig. 1A), with the minimum band
density (average of 0.54-fold of the control, n ¼ 3) of 0.5 lmol/
L of Cy3G at 12 min. On the other hand, after treatment with
0.5 lmol/L of Cy3G the peak of phosphorylation at Ser1179
occurred at 10–15 min. It should be noted that the depho-
sphorylation at Ser116 was sustained for over 30 min (Fig. 1B).
3.2. Relationship among Src, Akt, and ERK1/2 MAP kinase
In a previous study, it was demonstrated that Cy3G treat-
ment results in rapid phosphorylations of Src and ERK1/2
kinase [18]. In the present study, we tested the role of Akt
kinase in mediating the Cy3G-induced phosphorylation of
eNOS. Cy3G stimulated the phosphorylation of Akt at Ser473
in a time-dependent manner, with a peak at 5–10 min
(Fig. 2A). We next examined the relationships among Src, Akt
and ERK1/2 kinase using the Src kinase inhibitor pp2, PI3
kinase inhibitor wortmannin, and MEK inhibitor PD98059.
Results showed that pp2 at 20 lmol/L blocked the phos-
phorylation of Src, Akt, and ERK1/2 kinase (Fig. 2B).
PD98059 at 10 lmol/L inhibited the phosphorylation of
ERK1/2 MAP kinase and wortmannin at 1lmol/L inhibited
the phosphorylation of Akt (Fig. 2B). However, PD98059 did
not suppress Akt.
3.3. Role of Src, Akt, ERK1/2, and calcineurin in the
Cy3G-induced phosphorylation of eNOS
We also found that pp2, wortmannin, and PD98059 mark-
edly inhibited the phosphorylation at Ser1179 (Fig. 3A), andthat the calcineurin inhibitor cyclosporin A at 100 nmol/L also
blocked the dephosphorylation at Ser116 (Fig. 3B). Transfec-
tion of the dominant-negative Akt cDNA eﬃciently inhibited
the phosphorylation at Ser1179 stimulated by Cy3G. In con-
trast, transfection of the wild-type Akt cDNA vector increased
the level of phosphorylation at Ser1179 stimulated by Cy3G
(Fig. 4). Thus, the ERK1/2, Akt, and the upstream Src are
necessary for enhanced enzymatic activity of eNOS in response
to Cy3G.
3.4. Cy3G aﬀected the association between eNOS and soluble
guanylyl cyclase
Soluble guanylyl cyclase (sGC) is an important down-
stream intracellular target of NO. A recent study reported
that the sGC b-subunit interacts directly with heat shock
protein 90 (HSP90) and indirectly with eNOS in endothelial
cells in response to eNOS-activating agonists [20]. Our results
demonstrated that Cy3G caused formation of the eNOS/sGC
complex (Fig. 5A), as determined by immunoprecipitation
with anti-eNOS antibody and by immunoblotting with anti-
sGC-b1 antibody. On pretreatment for 30 min with gelda-
namycin (10 mg/ml), a speciﬁc inhibitor of HSP90 activity
Fig. 2. Interaction among Src, Akt, and ERK1/2. (A) BAECs were
treated with 0.5 lmol/L of Cy3G for the period indicated. (B) After
pretreatment with pp2 at 20 lmol/L, wortmannin at 1lmol/L, or
PD98059 at 10 lmol/L for 30 min, BAECs were stimulated with 0.5
lmol/L of Cy3G. Top: an original bolt. Bottom: results of densito-
metric analyses. Data are means S.E.M. (each n ¼ 3, *P < 0:01 vs.
control; #P < 0:01 vs. Cy3G).
Fig. 3. Inhibitory eﬀect of pp2, wortmannin, PD98059 or cyclosporin
A on the phosphorylation at Ser1179 or dephosphorylation at Ser116
in eNOS. (A) After pretreatment with pp2 at 20 lmol/L, wortmannin
at 1 lmol/L, or PD98059 at 10 lmol/L for 30 min, BAECs were sti-
mulated with 0.5 lmol/L of Cy3G. (B) After pretreatment with cy-
closporin A at 100 nmol/L for 60 min, BAECs were stimulated with 0.5
lmol/L of Cy3G. Top: an original bolt. Bottom: results of densito-
metric analyses. Data are meansS.E.M. (n ¼ 3, *P < 0:01).
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Furthermore, Cy3G increased production of cGMP (Fig. 5B)
(control: 0.341 0.039 pmol/ml vs. Cy3G: 0.498 0.044
pmol/ml, n ¼ 4, P < 0:05), however, pretreatment with L-
NAME (50 lmol/L) or wortmannin (1 lmol/L) abolished this
rise in production (Fig. 5B, each n ¼ 4, P < 0:05). Cy3G also
stimulated phosphorylation at Ser239 of the VASP, a sensi-
tive monitor of defective NO/cGMP signaling [22]. The
phosphorylation of VASP occurred 10 min after the treat-
ment with Cy3G (Fig. 5C).4. Discussion
Several studies have demonstrated that anthocyanins
protect against endothelial dysfunction and inhibit en-
dothelial cell apoptosis [6–9,23]. Two studies reported that
dietary anthocyanins, such as Cy3G, are directly absorbed in
rats and humans, appear in the blood, and are excreted
intact in urine [24,25], suggesting that the glucoside form of
cyanidin is important. The present study demonstrates that
Cy3G had an acute eﬀect on eNOS through non-transcrip-
tional activation, and induced phosphorylation at Ser1179
and dephosphorylation at Ser116 of eNOS in BAECs. After
treatment with 0.5 lmol/L of Cy3G for 12 min, phosphor-
ylation at Ser1179 rose up to 2-fold, while depho-
sphorylation at Ser116 decreased to 54% of the control level
(Fig. 1).
Fig. 4. Dominant negative Akt inhibited the Cy3G-induced phos-
phorylation of eNOS at Ser1179. Transfections are described in detail
under Section 2. The phosphorylation of eNOS at Ser1179 was assayed
by Western blotting. Top: an original bolt. Bottom: results of densi-
tometric analyses. Data are meansS.E.M. (n ¼ 3, *P < 0:01).
Fig. 5. Cy3G regulated interaction between eNOS and sGC, increased
production of cGMP, and induced phosphorylation of VASP.
(A) BAECs were pretreated with or without geldanamycin (10 mg/ml)
for 30 min and then stimulated with 0.5 lmol/L of Cy3G for 15 min.
(B) BAECs were pretreated with or without L-NAME or wortmannin
(wort) for 30 min and stimulated with 0.5 lmol/L of Cy3G for 3 h. The
cGMP concentration (pmol/106 cells/3 h) was measured with an
ELISA immunoassay. (C) BAECs were treated with 0.5 lmol/L of
Cy3G for the period indicated. Top: an original bolt. Bottom: results
of densitometric analyses. Data are meansS.E.M. (n ¼ 3 or 4,
*P < 0:05).
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Src, Akt, ERK1/2 and calcineurin were involved in the cellular
response after Cy3G treatment. Cy3G rapidly caused the
phosphorylation of Src (Tyr416), Akt (Ser473), and ERK1/2.
The phosphorylation of Akt and ERK1/2 paralleled that of
eNOS (Ser1179) (Figs. 1B and 2A). Inhibition of PI3K/Akt
and MEK/ERK1/2 prevented phosphorylation of eNOS at
Ser1179 by the inhibitors wortmannin and PD98059 (Fig. 3A)
or by transfection of the dominant-negative Akt cDNA
(Fig. 4), consistent with the well-established role of Akt [26,27]
and ERK1/2 [12,14–16] in the phosphorylation of eNOS.
Furthermore, the peak of phosphorylation of Src occurred
after 5–10 min [18], earlier than that of eNOS at Ser1179. A
speciﬁc inhibitor of Src (pp2) blocked the phosphorylation of
Src, Akt, ERK1/2, and eNOS (Ser1179) (Figs. 2B and 3A),
whereas an inhibitor of PI3K, wortmannin, and MEK,
PD98059, did not prevent the phosphorylation of Src (Fig. 2B,
top panel). These results suggest that Src lies upstream of Akt,
ERK1/2, and eNOS. Moreover, wortmannin did not aﬀect
ERK1/2 and PD98059 did not change Akt. It seems that these
two kinases do not depend on each other, and that there is no
crosstalk between the Akt and ERK1/2 signaling pathways,
consistent with the ﬁndings of Hisamoto et al. [10] and Mineo
et al. [13]. Recent studies have shown that Src is involved in the
phosphorylation of eNOS during shear stress [14,15], estrogen
treatment [11], or exposure to high-density lipoprotein [13].
Bauer et al. [28] indicated that Ser116 of eNOS acts as a
negative regulatory site and is important for the response to
agonists. Kou et al. [17] reported that the agonist VEGF
promotes dephosphorylation of eNOS at Ser116 in endothelial
cells. In the present study, we observed that Cy3G treatment
also resulted in the dephosphorylation of eNOS at Ser116
(Fig. 1A and B). Cyclosporin A at 100 nmol/L completely
blocked this dephosphorylation (Fig. 3B).The phosphorylation of eNOS at Ser1179 leads to aug-
mented enzyme activity, as evidenced by the regulated asso-
ciation between eNOS and sGC, the increase in production of
cGMP, and the phosphorylation induced at Ser239 of VASP
after treatment with Cy3G. Recently, sGC was found in ca-
veolae of endothelial cells [29]. Our results showed that Cy3G
caused formation of this sGC/eNOS complex. Pretreatment
with geldanamycin for 30 min signiﬁcantly suppressed the
180 J.-W. Xu et al. / FEBS Letters 574 (2004) 176–180formation (Fig. 5A). Furthermore, Cy3G stimulated phos-
phorylation at Ser239 of VASP (Fig. 5C) as a sensitive monitor
of defective NO/cGMP signaling [22].
We demonstrated that the dietary anthocyanin Cy3G acts as
a natural activator of eNOS in endothelial cells by promoting
its phosphorylation at Ser1179 and dephosphorylation at
Ser116. The results ameliorating endothelial function may in
part explain the protective eﬀects of plant-derived ﬂavonoids
on cardiovascular diseases.References
[1] Renaud, S. and de Lorgeril, M. (1992) Lancet 339, 1523–1526.
[2] Lorenz, M., Wessler, S., Follmann, E., Michaelis, W., Dusterhoft,
T., Baumann, G., Stangl, K. and Stangl, V. (2004) J. Biol. Chem.
279, 6190–6195.
[3] Wallerath, T., Deckert, G., Ternes, T., Anderson, H., Li, H.,
Witte, K. and Forstermann, U. (2002) Circulation 106, 1652–1658.
[4] Freeman, J.E., Park, C., Li, L., Perlman, J.A., Frei, B., Ivanov,
V., Deak, L.R., Iafrati, M.D. and Folts, J.D. (2001) Circulation
103, 2792–2798.
[5] Benito, S., Lopez, D., Saiz, M.P., Buxaderas, S., Sanchez, J., Puig-
Perellada, P. and Mitiavila, M.T. (2002) Br. J. Pharmacol. 135,
910–916.
[6] Noda, Y., Kaneyuki, T., Mori, A. and Packer, L. (2002) J. Agric.
Food Chem. 50, 166–171.
[7] Seeram, N.P., Momin, R.A., Nair, M.G. and Bourquin, L.D.
(2001) Phytomedicine 8, 362–369.
[8] Serraino, I., Dugo, L., Dugo, P., Mondello, L., Mazzon, E.,
Dugo, G., Caputi, A.P. and Cuzzocrea, S. (2003) Life Sci. 73,
1097–1114.
[9] Amorini, A.M., Lazzarino, G., Galvano, F., Fazzina, G., Tavazzi,
B. and Galvano, G. (2003) Free Radic. Res. 37, 453–460.
[10] Hisamoto, K., Ohmichi, M., Kanda, Y., Adachi, K., Nishio, Y.,
Hayakawa, J., Mabuchi, S., Takahashi, K., Tasaka, K., Miya-
moto, Y., Taniguchi, N. and Murata, Y. (2001) J. Biol. Chem.
276, 47642–47649.
[11] Haynes, M.P., Li, L., Sinha, D., Russell, K.S., Hisamoto, K.,
Baron, R., Collinge, M., Sessa, W.C. and Bender, J.R. (2003) J.
Biol. Chem. 278, 2118–2123.[12] Chambliss, K.L., Yuhanna, I.S., Mineo, C., Liu, P., German, Z.
and Sherman, T.S. (2000) Circ. Res. 87, e44–e52.
[13] Mineo, C., Yuhanna, I.S., Quon, M.J. and Shaul, P.W. (2003) J.
Biol. Chem. 278, 9142–9149.
[14] Boo, Y.C., Sorescu, G., Boyd, N., Shiojima, I., Walsh, K., Du, J.
and Jo, H. (2002) J. Biol. Chem. 277, 3388–3396.
[15] Davis, M.E., Cai, H., Drummond, G.R. and Harrison, D.G.
(2001) Circ. Res. 89, 1073–1080.
[16] Bernier, S.G., Haldar, S. and Michel, T. (2000) J. Biol. Chem. 275,
30707–30715.
[17] Kou, R., Greif, D. and Michel, T. (2002) J. Biol. Chem. 277,
29669–29673.
[18] Xu, J.-W., Ikeda, K. and Yamori, Y. (2004) Hypertension 44,
217–222.
[19] Xu, J.-W., Ikeda, K., Yamori, Y., 2004. Hypertens Res. 27, in
press.
[20] Nedvetsky, P.I., Sessa, W.C. and Schmidt, H.H. (2002) Proc.
Natl. Acad. Sci. USA 99, 16510–16512.
[21] Grenert, J.P., Sullivan, W.P., Fadden, P., Haystead, T.A.J., Clark,
J., Mirrmaugh, E., Krutzsch, H., Ochel, H.J., Schulte, T.W.,
Sausville, E., Neckers, L.M. and Toft, D.O. (1997) J. Biol. Chem.
272, 23843–23850.
[22] Oelze, M., Mollnau, H., Hoﬀmann, N., Warnholtz, A., Bod-
enschatz, M., Smolenski, A., Walter, U., Skatchkov, M.,
Meinertz, T. and Munzel, T. (2000) Circ. Res. 87, 999–1005.
[23] Martin, S., Giannone, G., Andriantsitohaina, R. and Martinez,
M.C. (2003) Br. J. Pharmacol. 139, 1095–1102.
[24] Matsumoto, H., Inaba, H., Kishi, M., Tominaga, S., Hiraya-
ma, M. and Tsuda, T. (2001) J. Agric. Food Chem. 49, 1546–
1551.
[25] Felgines, C., Texier, O., Besson, C., Fraisse, D., Lamaison, J.L.
and Remesy, C. (2002) J. Nutr. 132, 1249–1253.
[26] Fulton, D., Gratton, J.-P., McCabe, T.J., Fontana, J., Fujio, Y.,
Walsh, K., Franke, T.F., Papapetropoulos, A. and Sessa, W.C.
(1999) Nature 399, 597–601.
[27] Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R.
and Zeiher, A.M. (1999) Nature 399, 601–605.
[28] Bauer, P.M., Fulton, D., Boo, Y.C., Sorescu, G.P., Kemp,
B.E., Jo, H. and Sessa, W.C. (2003) J. Biol. Chem. 278,
14841–14849.
[29] Zabel, U., Kleinschnitz, C., Oh, P., Nedvetsky, P., Smolenski, A.,
Muller, H., Kronich, P., Kugler, P., Walter, U., Schnitzer, J.E.
and Schmidt, H.H. (2002) Nat. Cell Biol. 4, 307–311.
